About sab biotherapeutics inc - SABS
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.
SABS At a Glance
SAB Biotherapeutics, Inc.
777 West 41st Street
Miami Beach, Florida 33140
| Phone | 1-605-679-6980 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | 4.26M | |
| Sector | Health Technology | Employees | 86 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SABS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.175 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.025 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.043 |
SABS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | 49,549.791 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SABS Liquidity
| Current Ratio | 9.461 |
| Quick Ratio | 9.461 |
| Cash Ratio | 9.043 |
SABS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | 3.864 |
| Return on Equity | 4.802 |
| Return on Total Capital | 2.707 |
| Return on Invested Capital | 4.574 |
SABS Capital Structure
| Total Debt to Total Equity | 3.928 |
| Total Debt to Total Capital | 3.78 |
| Total Debt to Total Assets | 3.41 |
| Long-Term Debt to Equity | 3.30 |
| Long-Term Debt to Total Capital | 3.175 |